Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 4Recruiting 2Terminated 1Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Melanoma 23Neoplasm Metastasis 14Leukemia, Myeloid, Acute 11Carcinoma, Renal Cell 10Neoplasms 8Kidney Neoplasms 8Skin Neoplasms 5Recurrence 5Leukemia 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Ovarian Neoplasms 4Lymphoma, Non-Hodgkin 4Colorectal Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Neuroblastoma 3Lymphoma, Follicular 3Congenital Abnormalities 3Carcinoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Head and Neck Neoplasms 2Carcinoma, Merkel Cell 2

Interventions

Dexamethasone 112Bortezomib 61Lenalidomide 49Cyclophosphamide 49Calcium Dobesilate 43pomalidomide 32Melphalan 31fludarabine 25Filgrastim 25carfilzomib 22fludarabine phosphate 21daratumumab 20Granulocyte Colony-Stimulating Factor 16Whole-Body Irradiation 15Antilymphocyte Serum 15dexamethasone acetate 14Mycophenolic Acid 14Thalidomide 13Tacrolimus 13Cyclosporine 13Busulfan 13Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Radiotherapy 9Etoposide 9belantamab mafodotin 8Rituximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Multiple Myeloma × Interleukin-2 × Clear all
NCT04887259 2025-01-27

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Lava Therapeutics

Phase 1 Terminated
16 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡